M35.3
Polymyalgia rheumatica
Clinical Classification Guidelines
Excludes Type 1
- polymyalgia rheumatica with giant cell arteritis (M31.5)
Medical Intelligence & Overview
Polymyalgia rheumatica is a condition that causes muscle pain and stiffness, primarily affecting older adults. It is characterized by inflammation in muscles and surrounding tissues, leading to discomfort and restricted movement. Although its exact cause remains unknown, this condition is often associated with other autoimmune disorders and inflammatory conditions.
Causes & Symptoms
Clinical Causes: The precise cause of polymyalgia rheumatica is not well understood. It is believed to involve immune system activity that causes inflammation. Genetic factors may play a role, with certain genes increasing susceptibility. Environmental factors and infections have also been considered potential triggers. It commonly occurs in individuals over 50 years of age, suggesting age-related immune system changes are influential.
Key Symptoms: Muscle pain and tenderness, particularly in the shoulders and hips. Morning stiffness lasting for more than an hour. Pain experienced during movement, such as lifting arms or getting out of bed. Swelling and warmth in affected muscles. General fatigue and a feeling of malaise. Occasional fever and weight loss. Difficulty with everyday activities due to muscle discomfort.
Diagnostic & Treatment
Diagnosis Path: Diagnosing polymyalgia rheumatica involves a combination of medical history assessment, physical examination, and laboratory tests. Doctors look for characteristic symptoms like muscle pain and morning stiffness. Blood tests, such as elevated erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), indicate inflammation. Sometimes, additional imaging tests like ultrasound or MRI are used to rule out other conditions. There is no specific test for polymyalgia rheumatica, so the diagnosis relies on clinical evaluation and exclusion of other diseases.
Treatment Protocols: Treatment typically includes corticosteroids like prednisone, which effectively reduce inflammation and alleviate symptoms. The dosage is usually tapered over time based on patient response. Additional medications may be used to manage side effects or concurrent health issues. Regular monitoring by healthcare professionals helps adjust treatment plans as needed. Non-steroidal anti-inflammatory drugs (NSAIDs) are generally less effective but may be considered for mild cases. Since corticosteroid therapy can have significant side effects, close medical supervision is essential, especially for long-term management.
Clinical Advice & FAQs
Billing Guidance
Is M35.3 a billable ICD-10 code?
Yes, M35.3 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report M35.3?
Clinical documentation must specify the nature of Polymyalgia rheumatica and any associated comorbidities for accurate reporting.
Cite this Clinical Reference